knowledge -WSS

knowledge

author：entertainment 2025-09-29 21:27:22 - browse：299

What’s a radiopharmaceutical? What does it mean to be Zepbound? And who’s to blame for a biotech blow-up?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. As so-called radiopharmaceuticals make headlines in oncology, we explore their fascinating scientific backstory and the biotech gold rush to make them. We also discuss the approval of Eli Lilly’s curiously named treatment for obesity, the latest implosion for a promising biotech company, and some news in the world of shareholder activism.

For more on what we cover, here’s the radiopharmaceuticals story; here’s the news on Lilly; here’s more on Ventyx Biosciences; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Roivant's CEO is a star, but biotech's black hole persists

hotspot

WSS

Readout Newsletter: Beam, Prozac, "TechBio" and more

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Study fuels hope CAR

CDC panel: People 65 and older should get a Covid spring booster shot

FDA clears Verve to begin U.S. study of gene

5 ways to address the shortage of health care workers

knowledge

knowledge

entertainment

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Are embryos people? Reproductive medicine's future depends on the answer

Duchenne breakthrough therapy leaves behind pioneering families

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

The high cost of giving birth even with insurance

J&J lung cancer data amount to new salvo against AstraZeneca

Drug repurposing or repositioning? The language matters

Smaller biotechs seek to piggyback on weight loss drug boom

BioMarin wins approval for gene therapy to treat hemophilia A

Roivant's CEO is a star, but biotech's black hole persists

focus

STAT Readout Newsletter: Biotech news today

Virtual repurposing can help discover new uses for existing drugs

STAT Readout: Friday, Oct. 20 biotech updates

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

hotspot

hotspot

focus

explore